PubMed Health⌕ Search

Biomedical subjects

S Kronheim

Publications and source records attributed to S Kronheim.

At least 19 recordsLinked to original sources
PubMed1993

Identification of regions in interleukin-1 alpha important for activity.

Saturation mutagenesis of the mature human interleukin-1 alpha (IL-1 alpha) gene has been performed. Following expression in Escherichia coli, the biological and receptor binding activities of the mutant proteins were examined. Most of the molecule could be altered with little effect on either function. More than 3,500 mutants were examined, and only 23 unique amino acid sequences were identified which resulted in an altered ratio of biological to binding activity when compared with wild-type IL-1 alpha. These proteins possessed mutations at 38 of the 159 amino acid residues in IL-1 alpha. Random mutagenesis at several of these positions identified further substitutions that affected activity. Examination of a model for IL-1 alpha localized most of the residues which altered activity along one face of the molecule. This region appears to be distinct from areas of IL-1 which have been postulated to make contact with IL-1 receptor.

Amino Acid Sequence↗
PubMed1991

The proteolytic activation of interleukin-1 beta.

Interleukin-1 beta (IL-1 beta) is released from an inactive precursor by a proteolytic cleavage. A monocytic protease has been identified that appears to be involved in the physiological activation of this cytokine. Two situations have been found in which precursor IL-1 beta exists without the monocytic processing enzyme, and in these cases other proteases, such as neutrophil elastase, cathepsin G and cathepsin L, may be involved in generating the active cytokine.

Cell Line↗
PubMed1988

Regulation of tumor necrosis factor/cachectin and IL-1 secretion in human mononuclear phagocytes.

To determine whether the production and secretion of TNF and IL-1 by human mononuclear phagocytes could be independently modulated, we examined secretion of TNF and IL-1 by fresh monocytes and monocytes pretreated with IFN-gamma or granulocyte macrophage CSF before LPS stimulation. TNF and IL-1 secretion were in part differentially modulated. Fresh monocytes secreted large amounts of TNF and IL-1 after LPS stimulation and less than 6% as much without LPS. The capacity to secrete TNF in response to LPS decreased slightly in cultured monocytes but was markedly augmented by IFN-gamma (approximately five-fold more than fresh monocytes). In contrast, cultured monocytes secreted less than 5% as much IL-1 as fresh monocytes and, although augmented by IFN-gamma, IL-1 secretion remained much less than by fresh monocytes. These differences in modulation were reflected by differences in the molecular mechanisms regulating TNF and IL-1 secretion. TNF secretion was regulated primarily by changes in the duration of increased transcription and by an apparent increase in translation or protein stability in response to LPS; greater than 95% TNF produced was secreted under all conditions. In contrast, the changes in IL-1 secretion reflected primarily post-transcriptional regulation of IL1-alpha mRNA, transcriptional and post-transcriptional regulation of IL-1 beta mRNA and a decrease in the fraction of IL-1 secreted by cultured compared with fresh monocytes (10 and 60%, respectively). Changes in translational efficiency or protein processing or stability appeared not to be important mechanisms regulating IL-1 secretion. Additional evidence that TNF and IL-1 can be differentially modulated was the selective decrease in TNF secretion and the failure of IFN-gamma to enhance TNF secretion by cultured monocytes from neonates, whereas results for IL-1 were similar with adult and neonatal monocytes. Results with tissue macrophages were similar to those with cultured monocytes. These results indicate that TNF and IL-1 production and secretion by mononuclear phagocytes can be differentially modulated, reflecting in part different mechanisms of regulation; this may allow them to play partially independent roles in the host immune response.

Adult↗
PubMed1986

Regulation of antibody production in vitro by granulocyte-macrophage colony stimulating factor.

The precise molecular characteristics and the mode of action of the T cell derived lymphokines which augment antibody production in vitro remain uncertain. The use of ill-defined culture supernatants to dissect the cellular interactions in vitro involved in antibody production can lead to ambiguous results as the factors may act either on a contaminating non-B-lymphoid population or directly on the B lymphocyte. We report herein the development of a system for measuring in vitro primary antibody responses by murine spleen cells in which endogenous lymphokine production has been minimized by the in vivo administration of cytotoxic antibodies to deplete T lymphocytes and the addition of the glucocorticosteroid, dexamethasone, throughout the culture period. Using such an assay, a lymphokine activity was detected which was capable of augmenting the plaque forming cell response. This lymphokine was present in culture supernatant derived from the lectin activation of the T cell lymphoma, LBRM-33 and was distinct from other known B cell activators, notably IL-2 and IFN gamma. Biochemical purification of this activity indicated that it might be identical to granulocyte-macrophage colony stimulating factor (GM-CSF). The use of recombinant-derived GM-CSF protein unambiguously showed the role of this lymphokine in antibody production. These experiments demonstrated for the first time, the involvement of a hematopoietic factor in antigen-specific immune responses. Moreover, these results demonstrated an important regulatory circuit in the generation of antibody producing B cells in which GM-CSF, derived from activated T cells, stimulates macrophage function.

Animals↗
PubMed1982

The nervous control of rat somatostatin, glucagon and insulin secretions.

Somatostatin-like-immunoreactivity (SLI), immunoreactive insulin (IRI), glucagon (IRG) and catecholamine concentrations were measured in rat portal plasma during electrical stimulation of the vagus and splanchnic nerves, and during experimentally-induced hypovolaemia and hypoxaemia. Blood pressure, arterial gases and pH were monitored and hepatic blood flow was estimated (EHBF). Stimulation of the vagus nerves induced an increase in IRG and IRI concentrations, but had different influences on SLI level according to the concomitant experimental conditions. Stimulation of the left splanchnic nerve induced a sharp rise in SLI, IRG and catecholamine concentrations, whereas IRI level decreased hypovolaemia and hypoxaemia. Phentolamine treatment augmented the basal IRI, IRG and SLI concentrations. It did not suppress the hypovolaemia-induced rise of IRG and SLI concentrations, but unmasked a strong IRI release. By contrast, propranolol and atropine reduced significantly the A and D cell responses to acute hypovolaemia. These results are consistent with a profound influence of pancreatic nerves on A, B and D cell functions, which should be taken into account for interpretation of results during in vivo experiments.

Animals↗
PubMed1981

A radioimmunoassay for neurotensin.

A specific radioimmunoassay for neurotensin has been developed with a sensitivity of 40 pg/ml. Neurotensin-like immunoreactivity in human plasma shows characteristics similar to synthetic neurotensin on Sephadex G-25 (f) gel chromatography.

Animals↗
PubMed1980

Substance P release from rat hypothalamus and spinal cord.

A specific and sensitive radioimmunoassay for substance P has been developed to study the release of immunoreactive substance P from incubated rat hypothalamus and rat spinal cord in vitro. Release was significantly increased in the presence of two depolarizing stimuli (56 mM KCl and 75 microM veratrine) and was calcium-dependent. The released immunoreactive material diluted in parallel with synthetic substance P and showed close identity on Sephadex chromatography. A neuromodulator role for the peptide in the central nervous system is suggested.

Animals↗
PubMed1979

Ultracentrifugation evidence for a somatostatin-binding protein in serum.

Using a technique of high speed centrifugation of serum and a well validated immunoassay for the measurement of serum somatostatin-like immunoreactivity, we have demonstrated that somatostatin, unlike other peptide hormones, appears to sediment with large molecular weight proteins. When synthetic somatostatin of increasing concentration was incubated with serum prior to ultracentrifugation, a linear plot of concentration of somatostatin added against concentration sedimenting (or apparently bound to protein) revealed an association curve. These data provide further evidence for the existence of a serum-binding protein for somatostatin.

Adult↗
PubMed1979

Immunoreactive somatostatin release from rat spinal cord in vitro.

A calcium-dependent release of immunoreactive somatostatin from rat spinal cord in vitro in response to two depolarising stimuli (60 mM KCl and 75 micrometer veratrine) has been demonstrated. Released somatostatin immunoreactivity comprised 0.53% of total tissue content, showed parallelism when serial dilutions were compared to the immunoassay dose-response curve and eluted similarly to synthetic somatostatin on Sephadex G-25 (f) chromatography. These results provide further evidence for a neurotransmitter or neuromodulator role for somatostatin in mammalian spinal cord.

Animals↗
PubMed1979

Growth hormone release inhibitory hormone-like immunoreactivity in pancreas and gut in streptozotocin diabetes in the rat and response to insulin administration.

In streptozotocin diabetes in the rat, growth hormone release-inhibitory hormone-like immunoreactivity (GHRIH-LI) content of pancreas, gastric antrum and colon was increased. Insulin therapy significantly lowered the increased pancreatic GHRIH-LI content but did not affect that of the gastric antrum and colon at the dosage used. The relevance of these findings in relation to pancreatic and gastrointestinal function in diabetes awaits clarification.

Animals↗
PubMed1979

Metabolic clearance and plasma half-disappearance time of exogenous somatostatin in man.

The MCR and half-disappearance time of exogenously administered somatostatin have been measured during and after cessation of a constant infusion. Studies were performed on normal volunteers and patients with chronic liver disease and failure. Immunoreactive somatostatin was measured by a sensitive and specific RIA using an antiserum directed against the core of the molecule. Normal subjects had a mean MCR of 1949 +/- 250 ml/min (28.4 +/- 4.2 ml/min . kg BW) (mean +/- SEM), similar to values found in five patients with chronic liver disease. However, patients with chronic renal failure showed a highly significant (P less than 0.001) lowering of the MCR (501 +/- 32.7 ml/min or 7.8 +/- 0.6 ml/min . kg). The rate of disappearance of somatostatin after infusion was linear for 7-10 min, after which a much slower component was observed. In normal subjects, the t 1/2 of the first component varied from 1.1-3.0 min, in patients with liver disease it varied from 1.2-4.8 min, and in patients with chronic renal failure it varied from 2.6-4.9 min. Exogenously administered somatostatin is rapidly cleared in normal subjects and patients with chronic liver disease, but the MCR in end stage chronic renal failure is markedly lowered. The kidney may have a role in the metabolic clearance of exogenously administered somatostatin, or uremia may impair catabolism nonspecifically.

Adult↗
PubMed1979

Tissue and serum somatostatin-like immunoreactivity in fed, 15-h-fasted, and 72-h-fasted rats.

Somatostatin-like immunoreactivity (SLI) was measured in extracts of gastric antrum, colon, pancreas, and central nervous system, as well as in unextracted portal and inferior vena caval serum from fed, 15-h-fasted, and 72-h-fasted rats. No differences were found in SLI in the central nervous system of the three groups. However, striking variations were found in the gastrointestinal tract and pancreas; the antrum, colon, and pancreas of 15-h-fasted rats contained the least SLI, the content being significantly elevated in these three areas after feeding and after a 72-h fast. Portal serum levels were highest after feeding but lowest in 72-h-fasted rats, in spite of high intestinal and pancreatic SLI content in both. These tissue and serum differences suggest a physiologic role for SLI in nutrient homeostasis not only at tissue level, but also putatively as a hormone in the portal system.

Animals↗